Literature DB >> 19789222

Untreated glioblastoma multiforme: increased myo-inositol and glutamine levels in the contralateral cerebral hemisphere at proton MR spectroscopy.

Kai Kallenberg1, Hans C Bock, Gunther Helms, Klaus Jung, Arne Wrede, Jan-Hendrik Buhk, Alf Giese, Jens Frahm, Herwig Strik, Peter Dechent, Michael Knauth.   

Abstract

PURPOSE: To use localized in vivo proton magnetic resonance (MR) spectroscopy of the contralateral hemisphere in patients with glioblastoma multiforme (GBM) to detect alterations in cerebral metabolites as potential markers of infiltrating GBM cells.
MATERIALS AND METHODS: The study was approved by the ethics committee, and written informed consent was obtained. Twenty-two patients with newly diagnosed and untreated GBM underwent in vivo single-voxel short echo time proton MR spectroscopy with a 3-T MR imaging system. Absolute metabolite concentrations in the hemisphere contralateral to the tumor were compared with data from five patients with low-grade gliomas (LGGs) and from a group of 14 age-matched control subjects by using analysis of variance and subsequent t tests or corresponding nonparametric tests.
RESULTS: In the contralateral hemisphere, MR spectroscopy revealed increased concentrations of myo-inositol and glutamine. Mean myo-inositol levels were significantly increased in patients with GBM (3.6 mmol/L +/- 0.8 [standard deviation]) relative to levels in control subjects (3.1 mmol/L +/- 0.6; P = .03) and tended to be higher relative to levels in patients with LGG (2.7 mmol/L +/- 0.8; P = .09). Mean glutamine concentrations in patients with GBM (3.4 mmol/L +/- 0.9) differed significantly from those in control subjects (2.7 mmol/L +/- 0.7; P = .01); mean concentrations in patients with GBM differed from those in patients with LGG (2.4 mmol/L +/- 0.5; P = .01). There were no significant differences between data in patients with LGG and in control subjects.
CONCLUSION: Increased concentrations of myo-inositol and glutamine in the contralateral normal-appearing white matter of GBM patients are consistent with mild astrocytosis and suggest the detectability of early neoplastic infiltration by using proton MR spectroscopy in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19789222     DOI: 10.1148/radiol.2533071654

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  22 in total

Review 1.  Metabolomic signature of brain cancer.

Authors:  Renu Pandey; Laura Caflisch; Alessia Lodi; Andrew J Brenner; Stefano Tiziani
Journal:  Mol Carcinog       Date:  2017-07-17       Impact factor: 4.784

Review 2.  Vaccine strategies for glioblastoma: progress and future directions.

Authors:  Christopher Jackson; Jacob Ruzevick; Henry Brem; Michael Lim
Journal:  Immunotherapy       Date:  2013-02       Impact factor: 4.196

3.  Metabolomics of human cerebrospinal fluid identifies signatures of malignant glioma.

Authors:  Jason W Locasale; Tamar Melman; Susan Song; Xuemei Yang; Kenneth D Swanson; Lewis C Cantley; Eric T Wong; John M Asara
Journal:  Mol Cell Proteomics       Date:  2012-01-12       Impact factor: 5.911

4.  Association of metabolite concentrations and water diffusivity in normal appearing brain tissue with glioma grade.

Authors:  Andrew A Maudsley; Bhaswati Roy; Rakesh K Gupta; Sulaiman Sheriff; Rishi Awasthi; Meng Gu; Nuzhat Husain; Sudipa Mohakud; Sanjay Behari; Daniel M Spielman
Journal:  J Neuroimaging       Date:  2013-11-19       Impact factor: 2.486

Review 5.  Glutamine Imaging: A New Avenue for Glioma Management.

Authors:  S Ekici; J A Nye; S G Neill; J W Allen; H-K Shu; C C Fleischer
Journal:  AJNR Am J Neuroradiol       Date:  2021-11-04       Impact factor: 3.825

Review 6.  The molecular profile of microglia under the influence of glioma.

Authors:  Wei Li; Manuel B Graeber
Journal:  Neuro Oncol       Date:  2012-05-09       Impact factor: 12.300

Review 7.  Imaging biomarkers of brain tumour margin and tumour invasion.

Authors:  S J Price; J H Gillard
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 8.  Clinical proton MR spectroscopy in central nervous system disorders.

Authors:  Gülin Oz; Jeffry R Alger; Peter B Barker; Robert Bartha; Alberto Bizzi; Chris Boesch; Patrick J Bolan; Kevin M Brindle; Cristina Cudalbu; Alp Dinçer; Ulrike Dydak; Uzay E Emir; Jens Frahm; Ramón Gilberto González; Stephan Gruber; Rolf Gruetter; Rakesh K Gupta; Arend Heerschap; Anke Henning; Hoby P Hetherington; Franklyn A Howe; Petra S Hüppi; Ralph E Hurd; Kantarci Kantarci; Dennis W J Klomp; Roland Kreis; Marijn J Kruiskamp; Martin O Leach; Alexander P Lin; Peter R Luijten; Malgorzata Marjańska; Andrew A Maudsley; Dieter J Meyerhoff; Carolyn E Mountford; Sarah J Nelson; M Necmettin Pamir; Jullie W Pan; Andrew C Peet; Harish Poptani; Stefan Posse; Petra J W Pouwels; Eva-Maria Ratai; Brian D Ross; Tom W Scheenen; Christian Schuster; Ian C P Smith; Brian J Soher; Ivan Tkáč; Daniel B Vigneron; Risto A Kauppinen
Journal:  Radiology       Date:  2014-03       Impact factor: 11.105

Review 9.  Glioblastoma Metabolomics-In Vitro Studies.

Authors:  Karol Jaroch; Paulina Modrakowska; Barbara Bojko
Journal:  Metabolites       Date:  2021-05-13

10.  Phospholipid metabolites in recurrent glioblastoma: in vivo markers detect different tumor phenotypes before and under antiangiogenic therapy.

Authors:  Elke Hattingen; Oliver Bähr; Johannes Rieger; Stella Blasel; Joachim Steinbach; Ulrich Pilatus
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.